- (1,853) - (2,991)
Gain on sale of subsidiary - 78,352 - 78,352
Income from discontinued
operations - 76,499 - 75,361
Net income $39,258 $54,914 $32,485 $37,867
Basic income (loss) per share from
continuing operations $0.69 ($0.39) $0.57 ($0.67)
Basic income per share from
discontinued operations - 1.37 - 1.35
Basic net income per share $0.69 $0.98 $0.57 $0.68
Weighted average number of shares
used in computing:
Basic net income per share 56,736 55,744 56,629 55,580
SELECTED BALANCE SHEET INFORMATION
June 30, December 31,
2008 2007
(unaudited)
Cash and investments $80,237 $100,444
Restricted cash 14,739 14,533
Total cash and investments and
restricted cash $94,976 $114,977
Working capital $90,722 $107,844
Total assets $96,444 $119,282
4% Convertible subordinated notes
due 2011 $18,967 $69,890
Total long-term liabilities $18,967 $70,975
Accumulated deficit $455,089 $487,574
Stockholders' equity $72,346 $38,465
'/>"/>SOURCE CuraGen Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine technology :1.
CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs2.
CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia3.
CuraGen Announces Top-Line Phase II Results on Velafermin4.
CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma5.
CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference6.
CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting7.
CuraGen Advances CR011-vcMMAE into Phase II8.
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma9.
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma10.
CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer11.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound